Crossmark

An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany

Crossref DOI link: https://doi.org/10.1186/s12872-018-0898-x

Published Online: 2018-08-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Borisenko, Oleg http://orcid.org/0000-0002-1361-2431
Müller-Ehmsen, Jochen

Lindenfeld, JoAnn

Rafflenbeul, Erik

Hamm, Christian
Funding

Funding for this research was provided by:

CVRx Inc.
License Information

Text and Data Mining valid from 2018-08-09
More Information

Article History

Received: 18 April 2017

Accepted: 25 July 2018

First Online: 9 August 2018

Ethics approval and consent to participate

: Clinical data were obtained by the manufacturer (CVRx Inc., Minneapolis, MN, USA) with patient consent and after ethical approval. For the aims of present study, no further ethical approval was required, because the data were supplied by the manufacturer in an anonymous form.

: Not applicable.

: OB is the employee of the medical consulting company Synergus AB, which received a grant from CVRx Inc. to develop a decision analytic model. JME has received speaker honoraria from CVRx Inc. JL provided paid consulting support to CVRx Inc. CH is the member of the Advisory Board to CVRx Inc. and has received speaker honoraria from CVRx Inc. ER does not have any conflict of interest to report.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.